Chinese medicine (CM) decoction placebo is one of the key factors restricting the placebo-controlled clinical trial of CM. In this article, based on the analysis of the diffificulties in preparing CM placebo, the production requirements for placebo were put forward. Moreover, in accordance with clinical practices, a production method and evaluation process of CM decoction placebo was proposed, to provide a reference for clinical research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11655-016-2538-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Cardiovasc Ther
January 2025
Centre for Evidence-Based Chinese Medicine Beijing University of Chinese Medicine, Beijing 100029, China.
Shengmai San (SMS) is a traditional Chinese medicine formula used for supplementing and and can mitigate symptoms related to malignant arrhythmia and heart failure. This systematic review aimed at exploring the effectiveness and safety of SMS for viral myocarditis (VMC). Eight databases from their inception to June 2023 were searched to identified randomized controlled trials (RCTs) focusing on SMS for VMC.
View Article and Find Full Text PDFArticle Synopsis
- Assisted reproductive technologies (ART) often struggle with low success rates, and East Asian traditional medicine (EATM), particularly acupuncture and herbal remedies, might improve outcomes for women undergoing ART.
- This study aims to assess the effectiveness and safety of EATM in boosting clinical pregnancy and live birth rates among women facing infertility during ART cycles.
- Involving 10,776 women from 37 randomized trials across various countries, the research utilizes systematic data extraction and statistical analysis to evaluate the impact of acupuncture and herbal treatments on ART success.
Clinical efficacy of Chinese herbal medicine formula for Graves' hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial.
J Ethnopharmacol
February 2025
Department of Endocrinology, Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, 110034, PR China. Electronic address:
Ethnopharmacological Relevance: According to the theory of traditional Chinese medicine, Graves' disease (GD) is called 'Ying Bing', which is a kind of goiter. Haizao Yuhu decoction, originated from the medical book of the Ming Dynasty 'Waikezhengzong', is a classic Chinese herbal formula for the treatment of 'Ying Bing' for more than 400 years. Pingkang granules, modified from the Chinese herbal formula Haizao Yuhu decoction specialized in GD, has shown effectiveness in several single-centre studies.
View Article and Find Full Text PDFCombining single-cell RNA sequencing and network pharmacology to explore the target of cangfu daotan decoction in the treatment of obese polycystic ovary syndrome from an immune perspective.
Front Pharmacol
October 2024
The First Clinical Medicine School, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Background: Polycystic ovary syndrome (PCOS) is a heterogeneous gynecological endocrine disorder linked to immunity. Cangfu Daotan Decoction (CFDT), a classic Chinese medicine prescription, is particularly effective in treating PCOS, specifically in patients with obesity; however, its specific mechanism remains unclear.
Methods: Part 1: Peripheral blood mononuclear cells were collected on egg retrieval day from obese and normal-weight patients with PCOS and healthy women undergoing fertilization (IVF)-embryo transfer.
Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.
Chin Med
November 2024
Department of Medical Oncology, Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, No.2, East Street, Ying Hua Yuan, Chao Yang District, Beijing, China.
Background: Irinotecan is a standard chemotherapeutic agent in small cell lung cancer (SCLC), however, as a common adverse reaction, diarrhea limits the use of irinotecan. Shengjiang Xiexin decoction (SXD) has been used in various gastrointestinal diseases in China two thousand years ago. We designed this clinical trial to supply more evidences on the use of SXD as prophylaxis for irinotecan-induced diarrhea, especially for high-risk population predicted by gene testing of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!